Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Rational fixed-dose combinations (FDCs; two or more active ingredients in a single-dosage form) of investigational agents that have not previously been marketed could provide advantages over monotherapies for serious, chronic, multi-factorial disorders, such as non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH). FDCs that harness distinct modes of action could enhance efficacy and/or tolerability. Furthermore, the simplified dosage schedule could increase the likelihood of treatment adherence and thus improve outcomes.